Neuronetics, Inc. Provides Standalone Earnings Guidance for the Fourth Quarter and Full Year 2024
November 12, 2024 at 07:10 am EST
Share
Neuronetics, Inc. provided standalone earnings guidance for the fourth quarter and full year 2024. for the quarter, on a standalone basis, the Company expects total worldwide revenue between $19.0 million and $20.0 million.
for the year, on a standalone basis the Company now expects total worldwide revenue to be between $71.0 million and $72.0 million.
Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
NEURONETICS, INC. 
